Awakn Life Sciences Past Earnings Performance
Past criteria checks 0/6
Awakn Life Sciences has been growing earnings at an average annual rate of 37%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 47.5% per year.
Key information
37.0%
Earnings growth rate
47.6%
EPS growth rate
Biotechs Industry Growth | 51.1% |
Revenue growth rate | -47.5% |
Return on equity | n/a |
Net Margin | -3,479.8% |
Last Earnings Update | 31 Jul 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Awakn Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Jul 24 | 0 | -3 | 2 | 1 |
30 Apr 24 | 0 | -4 | 3 | 1 |
31 Jan 24 | 0 | -4 | 3 | 1 |
31 Oct 23 | 0 | -3 | 4 | 1 |
31 Jul 23 | 0 | -3 | 4 | 1 |
30 Apr 23 | 0 | -3 | 3 | 1 |
31 Jan 23 | 0 | -5 | 4 | 1 |
31 Oct 22 | 0 | -8 | 5 | 3 |
31 Jul 22 | 0 | -10 | 6 | 3 |
30 Apr 22 | 0 | -18 | 7 | 4 |
31 Jan 22 | 0 | -16 | 6 | 3 |
31 Oct 21 | 0 | -13 | 4 | 2 |
Quality Earnings: AWKN is currently unprofitable.
Growing Profit Margin: AWKN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AWKN is unprofitable, but has reduced losses over the past 5 years at a rate of 37% per year.
Accelerating Growth: Unable to compare AWKN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AWKN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: AWKN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.